Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label long-term safety and efficacy study of TAK-279 in moderate to severe plaque psoriasis
CTR20251323Phase 3Active
- Sponsor
- Takeda
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zasocitinib in plaque psoriasis, sponsored by Takeda. Started Jun 2025; status: active.
02
Drugs
zasocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20251323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251323.